key: cord-0775778-receea53 authors: Engelen, Matthias M.; Vandenbriele, Christophe; Spalart, Valérie; Martens, Caroline P.; Vandenberk, Bert; Sinonquel, Pieter; Lorent, Natalie; De Munter, Paul; Willems, Rik; Wauters, Joost; Wilmer, Alexander; Dauwe, Dieter; Gunst, Jan; Guler, Ipek; Janssens, Stefan; Martinod, Kimberly; Pieters, Griet; Peerlinck, Kathelijne; Verhamme, Peter; Vanassche, Thomas title: Thromboprophylaxis in COVID‐19: Weight and severity adjusted intensified dosing date: 2022-04-05 journal: Res Pract Thromb Haemost DOI: 10.1002/rth2.12683 sha: b662a5124d3be5104562efff9eaf4c1dbdd56655 doc_id: 775778 cord_uid: receea53 BACKGROUND: Venous thromboembolism (VTE) frequently occurs in hospitalized patients with coronavirus disease 2019 (COVID‐19). The optimal dose of anticoagulation for thromboprophylaxis in COVID‐19 is unknown. AIMS: To report VTE incidence and bleeding before and after implementing a hospital‐wide intensified thromboprophylactic protocol in patients with COVID‐19. METHODS: On March 31, 2020, we implemented an intensified thromboprophylactic protocol consisting of 50 IU anti‐Xa low molecular weight heparin (LMWH)/kg once daily at the ward, twice daily at the intensive care unit (ICU). We included all patients hospitalized in a tertiary care hospital with symptomatic COVID‐19 between March 7 and July 1, 2020. The primary outcome was the incidence of symptomatic or subclinical VTE and major bleeding during admission. Routine ultrasound screening for VTE was performed whenever logistically possible. RESULTS: We included 412 patients, of which 116 were admitted to the ICU. Of 219 patients with standard a prophylactic dose of LMWH, 16 (7.3%) had VTE, 10 of which were symptomatic (4.6%). Of 193 patients with intensified thromboprophylaxis, there were no symptomatic VTE cases, three incidental deep venous thrombosis cases (1.6%), and one incidental pulmonary embolism (0.5%). The major bleeding rate was 1.2% in patients with intensified thromboprophylaxis and 7.7% when therapeutic anticoagulation was needed. CONCLUSION: In hospitalized patients with COVID‐19, there were no additional symptomatic VTEs and a reduction in incidental deep vein thrombosis after implementing systematic thromboprophylaxis with weight‐adjusted prophylactic (ward) to intermediate (ICU), but not therapeutic dosed anticoagulation. This intensified thromboprophylaxis was associated with a lower risk of major bleeding compared with therapeutic dosed anticoagulation. One and a half years after the first outbreak in Wuhan, China, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 305 million confirmed cases of infection and more than 5 million known deaths worldwide as of January 10, 2022. 1 Clinicians quickly learned that the coronavirus disease 2019 (COVID-19) is associated with a high incidence of symptomatic venous thromboembolism (VTE) in hospitalized patients, especially in patients on intensive care units (ICUs). Systematic screening for VTE in patients hospitalized with COVID-19 has also revealed a higher incidence of subclinical VTE, even in patients receiving prophylactic doses of low molecular weight heparin (LMWH). [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Furthermore, more extensive activation of the coagulation system has been associated with worse clinical outcomes, and the use of LMWH in intermediate or therapeutic doses has been suggested to improve outcome in patients hospitalized with COVID-19. [13] [14] [15] [16] [17] [18] Many studies have focused on identifying the optimal dose of LMWH for in-hospital thromboprophylaxis. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] However, the results of these studies were not yet available to guide treatment in the large number of patients hospitalized early in the pandemic, resulting in high variability in institutional guidance for COVID-19 thromboprophylaxis. 31 Although the standard of care, fixed-dose use of LMWH seemed insufficient to prevent VTE in high-risk (ICU) patients, early reports warned for an increased risk of major bleeding with therapeutic doses of LMWH in the critically ill. 32, 33 Therefore, the optimal thromboprophylactic scheme was unknown. In March 2020, during the first peak of SARS-CoV-2 infections in Belgium, a hospital-wide thromboprophylactic protocol was implemented for hospitalized COVID-19 patients in an attempt to balance VTE prevention and bleeding risk in the absence of good evidence. In this "intensified prophylactic dose" protocol, typical prophylactic doses of LMWH were adjusted based on body weight and disease severity, with higher doses for ICU patients and weight-adjusted increases in LMWH dose. Full therapeutic doses (1 mg/kg twice daily) were not used for thromboprophylaxis but restricted to patients with prior indication for therapeutic anticoagulation with known VTE. While awaiting randomized data, we analyzed the safety and efficacy of our center's protocol. These, meanwhile published, randomized trials provide some interesting data, but there are still open questions on the optimal thromboprophylactic dosing in clinical practice. We, therefore, report our single-center observation of the safety and efficacy of this "intensified prophylactic" dosing strategy. subclinical VTE and major bleeding during admission. Routine ultrasound screening for VTE was performed whenever logistically possible. Given the preliminary reports on the high incidence of thrombotic complications in hospitalized COVID-19 patients, 6,7 clinicians were educated to be highly observant for signs of thrombotic complications and apply a low threshold for diagnostic imaging. Additionally, because of these alarming reports, clinicians started screening for deep venous thrombosis (DVT) in some ICU patients early on. Routine screening with venous duplex-ultrasound (CX 50 ad Sparq, Philips), aimed toward all ICU and ward patients, was initiated once logistically feasible given the challenging circumstances The primary outcome of this study was the in-hospital incidence of The hospitalization with the intensified protocol and 82 (71%) were admitted before the implementation of this protocol. The median age was 68 years (IQR 57-81), and 58% were male. Nine percent of patients had a history of VTE before hospitalization. The median hospital stay was 11 days (IQR 6-20); 28% of patients had been admitted to the ICU with a median ICU stay of 12 days (IQR 7-24). Of those critically ill patients, 62% needed invasive mechanical ventilation and 11% required ECMO. At admission, 17% of all patients were on therapeutic anticoagulation and 25% on antiplatelet therapy ( Table 2) . Sequential groups ("standard" thromboprophylaxis, before March 31, and "intensified" thromboprophylaxis, after March 31) were comparable in terms of basic characteristics and in-hospital severity parameters (Table 2) . At the ward, there was a higher per- Of the 219 patients who (initially) received standard-dosed thromboprophylaxis, 16 (7.3%) were diagnosed with VTE during hospitalization, 10 of whom were symptomatic (4.6%) ( Figure 2 in the ACTION trial, also had increased bleeding without improved outcome. 25 In the RAPID COVID COAG trial, therapeutic dosages were not associated with an increased bleeding risk but did not improve the composite outcome (death, invasive mechanical (2) ( The open-label INSPIRATION trial compared intermediate-with prophylactic-dosed heparin in ICU patients with a composite primary endpoint of adjudicated venous or arterial thrombosis, treatment with ECMO, or mortality within 30 days. 28 There was no statistical difference in the composite endpoint between the two strategies. However, the most critically ill patients were excluded, and the studied population was not as critically ill as can be expected from an ICU population. For example, the incidence of mechanical ventilation was around 20% in both groups compared with more than 60% in our ICU population. Recently, a meta-analysis comparing therapeutic dosages of heparin with lower dosages concluded that therapeutic heparin is beneficial in moderatelybut not critically-ill patients. 29 However, one should be careful drawing definite conclusions because studies included in the meta-analysis have their limitations. The most weighted study in the moderately ill meta-analysis is the multiplatform trial discussed earlier, with only 79% of patients in the therapeutic group receiving full-dose anticoagulation. Additionally, the patients in the HEP-COVID trial represent a subset of patients with high D-dimer levels (four times the upper limit of normal). Furthermore, when looking at D-dimer subgroups in the multiplatform trial, only the overall cohort showed a significant risk difference and odds ratio confidence interval with "a high probability of superiority" for therapeutic dose anticoagulation; this was not the case in patients with low levels of D-dimers (less than two times upper limit of normal). Additionally, patients with a substantial bleeding risk or absolute indication for anticoagulation were excluded in these studies. 38 Our data suggest that striving to monitored weight-adjusted intermediate doses in the critically ill and weight-adjusted prophylactic F I G U R E 3 Incidence of major bleeding. doses at the wards may represent a good balance between thromboprophylaxis and bleeding. This is further supported by the higher major bleeding rate we report in those patients who received therapeutic-dosed LMWH compared with lower-than-therapeuticdosed LMWH in our population, considering that our intensified but nontherapeutic COVID-19 protocol seems to prevent VTE effectively. These results could still be in line with randomized data because one-half of the ICU patients in the control group of the multiplatform trial received intermediate dosages. Therapeutic concentrations in ward patients seemed beneficial primarily in high-risk patients with elevated D-dimer levels (two to four times the upper limit of normal), which was not the case in most of our ward population. Bleeding risk in ward patients treated with therapeutic dosages was not significantly higher in most studies, but we need to be careful to extrapolate these findings to the general ward population because patients with a substantial bleeding risk or an absolute indication for anticoagulation were excluded from the randomized trials. This study's strengths include a large number of wellcharacterized patients treated at a tertiary center for COVID-19. We were able to treat 193 patients according to the intensified protocol from admission onward and add a supplemental sensitivity analysis for the observed symptomatic VTE rate through a systematic ultrasound screening in up to 50% of the critically ill in this group. The low incidence of incidental VTE in patients receiving the intensified COVID-19 protocol strengthens the idea that the underestimation of VTE in this group is negligible. Anti-Xa assays are integrated into the routine hospital laboratory, making monitoring of ICU patients and challenging cases readily available. This level of monitoring provides insights into the accumulation of LMWH, for example, in patients with progressive renal failure, or underdosing, typically, in obese patients. As a safety recommendation, physicians were encouraged to measure anti-Xa levels in critically ill patients. Dose adjustment based on these levels was left to the clinician's discretion, with support of the department of thrombosis and hemostasis, considering the clinical context. Therefore, it is unclear to which extent anti-Xa measurements have contributed to the efficacy and safety of our protocol. Because of its retrospective and sequential nature, this study also has several limitations. Importantly, due to the lack of randomization and the sequential design during an emergency state during the pandemic with a rapidly changing clinical practice, it is not possible to confirm a causal relation between the intensified thromboprophylaxis strategy and the lower rates of VTE. As discussed in the Methods, this emergency state also prohibited routine venous ultrasound screening in all hospitalized patients at a predefined time point in the early phase of the pandemic. As resources became more readily available, we eventually screened up to 50% of the critically ill patients receiving the intensified protocol during hospitalization. This lack of systematic imaging does not affect the diagnosis of symptomatic VTE but is a major limitation when assessing asymptomatic DVT. However, this limitation was inherent to the timing of the study early in the pandemic and the limited resources at that time. As screening became more frequent after adopting the intensified thromboprophylaxis protocol, a higher proportion of patients was screened during the second part of the study. Thus, there is less potential for underestimating the true VTE incidence in patients receiving intensified versus standard thromboprophylaxis. Therefore, it is unlikely that more systematic screening would have affected our main findings. Last, given the relatively few events in the outcomes of interest-VTE and major bleeding-an adjusted multivariate model could not be adequately performed. Consequently, the reported findings should be interpreted cautiously. Our retrospective analysis seems in line with available randomized data that strictly prophylactic doses of heparin may not be sufficiently effective to prevent venous thromboembolism in patients hospitalized with severe COVID-19. Randomized trials have shown that systematically using therapeutic doses of heparin was associated with an increased bleeding risk in several subgroups of patients, most importantly in critically ill patients. Our data show that a patient-tailored approach to anticoagulation with intensified prophylactic, but not therapeutic doses of heparin, was associated with high efficacy to prevent thromboembolism and a low bleeding risk in our population. Together with the results of randomized trials, this study stresses the importance of (1) a hospital-wide protocol and (2) higher than prophylactic-dosed anticoagulation in selected patients. In hospitalized patients with COVID-19, we report no symptomatic VTE and a decrease in screening-detected incidental DVT after implementing systematic thromboprophylaxis with weight-adjusted prophylactic (ward) to intermediate (ICU), but not therapeutic doses of LMWH. This strategy was associated with a low risk of major bleeding in patients receiving intensified but non-therapeutic dosed thromboprophylaxis. We are grateful to all patients, their family members, and all health care workers who helped to perform clinical studies in extraordinary and challenging times during this COVID-19 pandemic, and by doing so contribute to fighting SARS-CoV-2. We also thank Jonas Hospitals Leuven, Belgium) for his collaboration and efforts for this project. The authors declare no conflicts of interest for the submitted work. All authors have read the manuscript and approved submis- World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. World Health Organization COVID-19 and its implications for thrombosis and anticoagulation Pulmonary embolism in COVID-19 patients: a French multicentre cohort study Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Venous thromboembolism in critically Ill patients with COVID-19: Results of a screening study for deep vein thrombosis Incidence of venous thromboembolism in hospitalized patients with COVID-19 VTE in ICU Patients With COVID-19 Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: a longitudinal controlled before-after study Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave Venous Thromboembolism in COVID-19 Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Thrombosis in hospitalized patients with COVID-19 in a New York city health system Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicentre Italian CORIST Study Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality Hypercoagulopathy in severe COVID-19: implications for acute care The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a U Prophylactic anticoagulants for people hospitalised with COVID-19 The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Communityacquired Pneumonia) study. Rationale and design Anti-thrombotic therapy to ameliorate complications of COVID-19 (ATTACC): study design and methodology for an international, adaptive Bayesian randomized controlled trial Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19 Therapeutic anticoagulation with heparin in critically ill patients with Covid-19 Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial Pharmacologic thromboprophylaxis and thrombosis in hospitalized patients with COVID-19: a pooled analysis Effect of intermediatedose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial Randomized trials of therapeutic heparin for COVID-19: a meta-analysis Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediatedose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial Variability in institutional guidance for COVID-19-associated coagulopathy in the United States Bleeding risk in hospitalized patients with COVID-19 receiving intermediateor therapeutic doses of thromboprophylaxis Therapeutic anticoagulation in critically ill patients with Covid-19 -preliminary report Anticoagulant therapy in COVID-19 critically ill: Should we go for more? Belgian clinical guidance on anticoagulation management in hospitalised and ambulatory patients with COVID-19 Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients International trials of blood thinners pause enrollment of critically ill COVID-19 patients. National Institute for Health Research Anticoagulation as a therapeutic strategy for hospitalised patients with COVID-19 Kimberly Martinod @Kmartinod Additional supporting information may be found in the online version of the article at the publisher's website.